HALIFAX, Nova Scotia–(BUSINESS WIRE)–Athletigen, the industry leader in athlete genomics, today announced the appointment of John Pereira to the Board of Directors. John previously led all Product, Marketing and Operational activities as the VP of AncestryDNA. He was ultimately responsible for taking the latest scientific advancements in human genomics and combining them with the world’s largest resource in family history to provide a new and simple online resource for discovering your past. “I have been involved in the genomics industry for nearly 10 years and after discussions with the Athletigen team, it was an easy decision to join the board,” said Pereira. “I’m excited to join such an amazing team and help advance discovery of genetic influence on athletic performance.” Adding someone as experienced in building genomics products as John was a natural fit for Athletigen. Providing strategic insight for facilitating the development & growth of the Athletigen product, John provides the experience necessary to help define and serve the emerging market of athlete genomics. With this unparalleled understanding of product development & marketing, Athletigen is prepared to deliver genomic insights to athletes around the world. “There are very few people in this industry who can say they have developed a successful genomics product and taken it to market, so to bring John’s experience to Athletigen was an easy decision, “ says Athletigen Founder & CEO, Dr. Jeremy Koenig. “We are delighted to be working with John because he brings world-class industry standards to a product that aims to help its users perform on a global stage.” Athletigen is a company driven by science and committed to helping athletes achieve their performance goals. Through genomic innovation with strategic partners, Athletigen works to deliver the most advanced research findings in human performance to its customers. About Athletigen At Athletigen, we believe that the more remarkable the athlete, the more unique they are and our mission is to help them honor their individual training requirements necessary for world class performance. The evolution of our product is driven by intense user research conducted with world class and Olympic athletes, as well as the professionals who train them. As are result, we give high-performers the chance to celebrate their differences and truly nurture their nature. www.athletigen.com.
BIONOVA CONTACT
#46 1344 Summer Street
Halifax, Nova Scotia
Canada B3H 0A8
Phone: 902-421-5705
Fax: 902-421-2733
Email: [email protected]
Halifax, Nova Scotia
Canada B3H 0A8
Phone: 902-421-5705
Fax: 902-421-2733
Email: [email protected]

Recent Posts
- MARS VR Lab
- Workinsights
- NEWS RELEASE: BioNova Announces MycoFutures North Atlantic as the Winner of the Eleventh Annual BioInnovation Challenge (BIC) at BioPort 2021
- NEWS RELEASE: BioNova’s BioPort 2021 Conference for Health and Life Sciences Kicks-Off Today
- NEWS RELEASE: BioNova Selects Eight Semi-Finalists to Participate in the 11th Annual BioInnovation Challenge
Business Wire National BioTech News
- Global Protein Labeling Market Report to 2028 - Featuring Thermo Fisher Scientific, Merck and PerkinElmer Among Others - ResearchAndMarkets.com
- Cybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical Trial
- Miravo Healthcare™ Announces Appointment of Anthony Snow to its Board of Directors
- Cybin Announces Results of Shareholders’ Meeting
- Revitalist Partners with Awakn Life Sciences as First Licensee in the United States to begin Redefining Treatment for Addiction, Recovery, and Relapse Prevention in the Psychedelic Space
- Personalis in Partnership with BC Cancer to Assess Clinical and Economic Benefits of ctDNA for Colorectal and Pancreatic Cancers
- Miravo Healthcare™ Announces Second Quarter 2022 Results
- Antibe Therapeutics Reports Q1 2023 Interim Financial and Operating Results
- Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2023
- Taro Pharmaceuticals Inc. Issues Voluntary Type I Recall of Taro-Zoledronic Acid Injection, 5 mg/100 mL, 100 mL Vial Due to Particulate Matter Over Specified Requirements
RECENT NEWS
- MARS VR Lab January 25, 2022
- Workinsights January 25, 2022
- NEWS RELEASE: BioNova Announces MycoFutures North Atlantic as the Winner of the Eleventh Annual BioInnovation Challenge (BIC) at BioPort 2021 November 8, 2021
- NEWS RELEASE: BioNova’s BioPort 2021 Conference for Health and Life Sciences Kicks-Off Today November 2, 2021
- NEWS RELEASE: BioNova Selects Eight Semi-Finalists to Participate in the 11th Annual BioInnovation Challenge August 24, 2021
- NEWS RELEASE: BioNova supports the Government of Canada’s biomanufacturing and life sciences strategy July 30, 2021
RECENT TWEETS
Over half of #AVF2022 Company Showcase participants are health and life sciences companies. The Showcase features some of Atlantic Canada’s most promising technology companies.
https://t.co/Es7CQqgHJd https://t.co/T3EKmIjZLN
https://t.co/Es7CQqgHJd https://t.co/T3EKmIjZLN
Nova Scotia Health launches pilot program with @Virtual_Hallway to connect primary care providers with specialists to improve patient access to specialist care and reduce wait times.
@NSHealthHub @HealthNS @Doctors_NS @NSCollegeNurses https://t.co/RTZtDwz6Hq
@NSHealthHub @HealthNS @Doctors_NS @NSCollegeNurses https://t.co/RTZtDwz6Hq